Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Date of Graduation
12-17-2021
Course Instructor
Abby Massey
Abstract
Objective: to assess whether SGLT2 inhibitors significantly reduce the risk of hospitalization for heart failure (HAHF) and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF). Design: systematic literature review. Methods: searches were conducted in PubMed with the terms "SGLT2 Inhibitors,” “heart failure with reduced ejection fraction (HFrEF),” and "hospitalization” and the following limits: publication within the last 5 years, clinical trials, meta-analyses, randomized control trials, humans, and English. These criteria determined the selected literature: randomized control trial (RCT), use of an SGLT2i compared to placebo, and outcomes including HAHF and/or cardiovascular related death. Results: DAPA-HF: 27% RRR in HAHF, 23% RRR of composite decrease for HAHF and cardiovascular death. NNT = 21(HAHF). EMPORER-REDUCED: 28% RRR in HAHF, 20% RRR composite decrease for HAHF and cardiovascular death. NNT = 19 (HAHF). CANVAS: 33% RRR of HAHF and 22% RRR for composite outcome of cardiovascular death and HAHF. NNT = 31 (HAHF). Conclusion: SGLT2is modestly reduced HAHF and cardiovascular death in HFrEF patients and may be an appropriate secondary adjunct to standard treatment for secondary prevention of HAHF and cardiovascular causes of death.
Recommended Citation
Jackson S, Mathis M. SGLT2 Inhibitors in the Management of Heart Failure with Reduced Ejection Fraction
